Omnicell, Inc.
OMCL
Positions held
Your positionsOMCL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Omnicell operates in the growing health information services industry, which is increasingly focused on automation and efficiency in healthcare delivery.
- Omnicell's revenue increased by 1% compared to the prior quarter, reaching $312 million.
- The company's gross margin improved to 49%, up from 45.3% in the previous quarter.
- Despite recent improvements, Omnicell's operating margin remains low, indicating potential challenges in cost management.
- In 2023, the company reported a net income of -$20.371 million, reflecting ongoing financial struggles.
- The operating margin for the year 2025 was only 0.44%, highlighting persistent profitability issues.
Fundamentals
| Market cap | $1.58B | Enterprise value | $1.50B | Trailing P/E | 41.46 | Forward P/E | 16.67 |
| PEG | 15.40 | Price / book | 1.23 | Beta | 0.99 | Dividend yield | 0.00% |
| Revenue growth | 7.5% | Earnings growth | 333.3% | Gross margin | 44.0% | Operating margin | 5.9% |
| Profit margin | 3.1% | ROE | 3.1% | ROA | 1.5% | Debt / equity | 0.15 |
| Current ratio | 1.64 | Free cash flow | $134.18M | Analyst recommendation | strong_buy | Mean target | $57.86 |
| 52w high | $55.00 | 52w low | $29.06 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $312M | $310M | $314M | $311M | $291M |
| Op margin | 10.4% | 5.4% | 0.1% | 2.7% | 2.8% |
| Net income | $24.3M | $11.4M | -$2.0M | $5.5M | $5.6M |
| Gross margin | 49.0% | 45.3% | 41.5% | 43.3% | 43.9% |
| Gross profit | $153M | $140M | $130M | $135M | $128M |
| Operating income | $32.4M | $16.9M | $0.4M | $8.2M | $8.1M |
- Revenue +1% vs prior quarter ($312M vs $310M).
- Gross margin 49% (was 45.3% prior quarter).
- Operating margin expanded to 10.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.1B | $1.3B |
| Op margin | 0.4% | 0.0% | -3.0% | -0.2% |
| Net income | $2.1M | $12.5M | -$20.4M | $5.6M |
| Gross margin | 42.5% | 42.3% | 43.3% | 45.4% |
| Gross profit | $503M | $471M | $497M | $589M |
| Operating income | $5.2M | $0.3M | -$34.9M | -$2.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
2026-10-07 · Does Omnicell’s Revenue Beat and Weak EBITDA Guidance Change The Bull Case For OMCL?
2026-10-06 · 1 Healthcare Stock with Exciting Potential and 2 We Find Risky
2026-10-05 · Healthcare Technology for Providers Stocks Q2 Recap: Benchmarking Omnicell (NASDAQ:OMCL)
2026-09-22 · Omnicell (OMCL) Stock Trades Below Fair Value After A 78% Slump
2026-09-21 · 3 Reasons OMCL is Risky and 1 Stock to Buy Instead
2026-09-18 · Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
2026-09-11 · 1 Cash-Heavy Stock to Target This Week and 2 We Question
2026-09-10 · 1 Cash-Producing Stock on Our Buy List and 2 We Ignore
2026-09-03 · TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
2026-09-03 · TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
2026-09-03 · TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
Price (daily)
Full chart · RSI · MACD · patterns